Scienture (SCNX)
Market Price (12/4/2025): $0.606 | Market Cap: $8.6 MilSector: Consumer Staples | Industry: Drug Retail
Scienture (SCNX)
Market Price (12/4/2025): $0.606Market Cap: $8.6 MilSector: Consumer StaplesIndustry: Drug Retail
Investment Highlights
Why It Matters
Which of these 2 stories sounds closer for this stock?
1. Generates cash flow
The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.
2. Riding a trend
Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -70% | Weak multi-year price returns2Y Excs Rtn is -133%, 3Y Excs Rtn is -162% | Penny stockMkt Price is 0.6 |
| Attractive yieldDividend Yield is 15% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -16 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -12825% | |
| Expensive valuation multiplesP/SPrice/Sales ratio is 115x | ||
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -76%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -74%, Rev Chg QQuarterly Revenue Change % is null | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -10365%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -10365% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -126% | ||
| High stock price volatilityVol 12M is 384% | ||
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 24% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -70% |
| Attractive yieldDividend Yield is 15% |
| Weak multi-year price returns2Y Excs Rtn is -133%, 3Y Excs Rtn is -162% |
| Penny stockMkt Price is 0.6 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -16 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -12825% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 115x |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -76%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -74%, Rev Chg QQuarterly Revenue Change % is null |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -10365%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -10365% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -126% |
| High stock price volatilityVol 12M is 384% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 24% |
Valuation, Metrics & Events
SCNX Stock
Why The Stock Moved
Qualitative Assessment
AI Generated Analysis | Feedback
1. Scienture's stock plummeted 43.7% following the announcement of a $3.9 million registered direct offering of common stock at a significant discount on August 14, 2025, with the offering expected to close on August 15, 2025.
2. The stock experienced a catastrophic decline of 39.62% on October 24, 2025, attributed to concerns over potential dilution from capital-raising activities, similar to a previous offering.
Stock Movement Drivers
Return vs. Risk
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SCNX Return | -20% | -55% | -83% | -14% | 87% | -91% | -99% |
| Peers Return | -5% | 1252% | -43% | -16% | 35% | -42% | 382% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 16% | 112% |
Monthly Win Rates [3] | |||||||
| SCNX Win Rate | 58% | 42% | 25% | 42% | 33% | 20% | |
| Peers Win Rate | 31% | 25% | 27% | 31% | 35% | 29% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 70% | |
Max Drawdowns [4] | |||||||
| SCNX Max Drawdown | -38% | -55% | -88% | -35% | -21% | -92% | |
| Peers Max Drawdown | -24% | -18% | -46% | -32% | -21% | -51% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HITI, WGRX, PETS, SCNX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/3/2025 (YTD)
How Low Can It Go
| Event | SCNX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -96.7% | -25.4% |
| % Gain to Breakeven | 2918.1% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -58.6% | -33.9% |
| % Gain to Breakeven | 141.5% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -76.0% | -19.8% |
| % Gain to Breakeven | 316.7% | 24.7% |
| Time to Breakeven | 252 days | 120 days |
Compare to HITI, WGRX, PETS, SCNX
In The Past
Scienture's stock fell -96.7% during the 2022 Inflation Shock from a high on 2/9/2021. A -96.7% loss requires a 2918.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Latest Trefis Analyses
| Title | Topic | |
|---|---|---|
| DASHBOARDS | ||
| Day 5 of Loss Streak for Scienture Stock with -70% Return (vs. -87% YTD) [10/30/2025] | Notification | |
| With Scienture Stock Sliding, Have You Assessed The Risk? | Return |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select past ideas related to SCNX. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11302025 | BF-B | Brown-Forman | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 3.1% | 3.1% | 0.0% |
| 11302025 | CPB | Campbell's | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | -1.9% | -1.9% | -1.9% |
| 11212025 | ENR | Energizer | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | -5.3% | -5.3% | -5.3% |
| 11212025 | FLO | Flowers Foods | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.5% | 3.5% | -1.6% |
| 11142025 | CLX | Clorox | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 2.1% | 2.1% | -5.1% |
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11302025 | BF-B | Brown-Forman | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 3.1% | 3.1% | 0.0% |
| 11302025 | CPB | Campbell's | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | -1.9% | -1.9% | -1.9% |
| 11212025 | ENR | Energizer | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | -5.3% | -5.3% | -5.3% |
| 11212025 | FLO | Flowers Foods | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.5% | 3.5% | -1.6% |
| 11142025 | CLX | Clorox | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 2.1% | 2.1% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Scienture
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 1.18 |
| Mkt Cap | 0.0 |
| Rev LTM | 132 |
| Op Inc LTM | -8 |
| FCF LTM | -3 |
| FCF 3Y Avg | 7 |
| CFO LTM | -0 |
| CFO 3Y Avg | 12 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -17.2% |
| Rev Chg 3Y Avg | -5.2% |
| Rev Chg Q | -4.1% |
| QoQ Delta Rev Chg LTM | -1.1% |
| Op Mgn LTM | -57.7% |
| Op Mgn 3Y Avg | -0.3% |
| QoQ Delta Op Mgn LTM | -0.2% |
| CFO/Rev LTM | -5.8% |
| CFO/Rev 3Y Avg | 5.0% |
| FCF/Rev LTM | -7.9% |
| FCF/Rev 3Y Avg | 3.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.0 |
| P/S | 1.0 |
| P/EBIT | -1.1 |
| P/E | -4.8 |
| P/CFO | 2.6 |
| Total Yield | -43.7% |
| Dividend Yield | 0.2% |
| FCF Yield 3Y Avg | 3.3% |
| D/E | 0.3 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -14.6% |
| 3M Rtn | -39.6% |
| 6M Rtn | -45.3% |
| 12M Rtn | -64.7% |
| 3Y Rtn | -87.7% |
| 1M Excs Rtn | -14.6% |
| 3M Excs Rtn | -43.7% |
| 6M Excs Rtn | -60.0% |
| 12M Excs Rtn | -75.5% |
| 3Y Excs Rtn | -161.9% |
Segment Financials
Revenue by Segment
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Integra | 1 | 5 | 3 | 10 | 1 |
| Scienture | 0 | ||||
| Unallocated | 0 | 0 | 0 | 0 | |
| Superlatus | 0 | ||||
| Trxade, Inc. | 5 | 5 | 6 | 5 | |
| Community Specialty Pharmacy, LLC (CSP) | 2 | 2 | 2 | ||
| Total | 1 | 10 | 10 | 17 | 7 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Scienture | 0 | ||||
| Integra | -1 | -1 | -3 | -1 | -0 |
| Unallocated | -17 | -5 | -4 | -4 | -2 |
| Superlatus | 0 | ||||
| Trxade, Inc. | 2 | 2 | 3 | 2 | |
| Community Specialty Pharmacy, LLC (CSP) | -0 | -1 | -0 | ||
| Total | -18 | -4 | -5 | -3 | -0 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Unallocated | 12 | 1 | 3 | 5 | 3 |
| Integra | 0 | 0 | 1 | 3 | 0 |
| Scienture | 0 | ||||
| Superlatus | 0 | ||||
| Trxade, Inc. | 2 | 2 | 2 | 2 | |
| Community Specialty Pharmacy, LLC (CSP) | -0 | -0 | 0 | ||
| Total | 13 | 4 | 6 | 10 | 6 |
Returns Analyses
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 6302025 | 8122025 | 10-Q 6/30/2025 |
| 3312025 | 5122025 | 10-Q 3/31/2025 |
| 12312024 | 3262025 | 10-K 12/31/2024 |
| 9302024 | 11062024 | 10-Q 9/30/2024 |
| 6302024 | 8092024 | 10-Q 6/30/2024 |
| 3312024 | 6262024 | 10-Q 3/31/2024 |
| 12312023 | 4222024 | 10-K 12/31/2023 |
| 9302023 | 1162024 | 10-Q 9/30/2023 |
| 6302023 | 8182023 | 10-Q 6/30/2023 |
| 3312023 | 5152023 | 10-Q 3/31/2023 |
| 12312022 | 3272023 | 10-K 12/31/2022 |
| 9302022 | 11072022 | 10-Q 9/30/2022 |
| 6302022 | 7252022 | 10-Q 6/30/2022 |
| 3312022 | 5092022 | 10-Q 3/31/2022 |
| 12312021 | 3282022 | 10-K 12/31/2021 |
| 9302021 | 10252021 | 10-Q 9/30/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |